Payment overview · 2025
General Payments
$1,523.51
74 reported records · 19 companies
Healthcare provider profile · identity verified
Michael Smar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FREEPORT, NY · NPI 1457349706
Verified facts
What the public records show
CMS Open Payments records show Michael Smar, MD received $1,523.51 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $255.36 | 16.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.26 | 15.1% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $206.51 | 13.6% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $192.94 | 12.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.03 | 11.3% | 9 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $70.68 | 4.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.55 | 4.0% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $48.32 | 3.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $45.95 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.62 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.91 | 2.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.66 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.12 | 1.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.90 | 1.4% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $19.99 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.15 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.77 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.72 | 1.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.07 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,523.51 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $255.36 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $206.51 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $192.94 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $108.46 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $103.17 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.86 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $76.70 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $70.68 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.86 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.86 | 5 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $60.55 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $60.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.95 | 4 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $45.95 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $21.24 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 227 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 528 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 391 | 103 |
| Losartan Potassium | Losartan Potassium | 329 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 94 |
| Alprazolam | Alprazolam | 293 | 76 |
| Simvastatin | Simvastatin | 288 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 71 |
| Eliquis | Apixaban | 227 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 51 |
| Metformin Hcl | Metformin Hcl | 204 | 70 |
| Omeprazole | Omeprazole | 195 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 32 |
| Furosemide | Furosemide | 150 | 53 |
| Gabapentin | Gabapentin | 149 | 44 |
| Ozempic | Semaglutide | 139 | 29 |
| Azithromycin | Azithromycin | 131 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 42 |
| Potassium Chloride | Potassium Chloride | 109 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 31 |
| Telmisartan | Telmisartan | 105 | 30 |
| Spironolactone | Spironolactone | 104 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 24 |
| Diazepam | Diazepam | 90 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 28 |
| Glimepiride | Glimepiride | 89 | 26 |
| Atenolol | Atenolol | 86 | 25 |
| Prednisone | Prednisone | 84 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 26 |
| Famotidine | Famotidine | 79 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Lisinopril | Lisinopril | 72 | 21 |
| Metolazone | Metolazone | 71 | 24 |
| Synthroid | Levothyroxine Sodium | 71 | 18 |
| Brilinta | Ticagrelor | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 19 |
| Allopurinol | Allopurinol | 59 | 21 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Lorazepam | Lorazepam | 52 | 11 |
| Repatha Sureclick | Evolocumab | 50 | 12 |
| Warfarin Sodium | Warfarin Sodium | 50 | 16 |
| Amoxicillin | Amoxicillin | 49 | 25 |
| Digoxin | Digoxin | 49 | 13 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Trazodone Hcl | Trazodone Hcl | 49 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 21 |
| Finasteride | Finasteride | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 12 |
| Jardiance | Empagliflozin | 42 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 39 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Lidocaine | Lidocaine | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | 11 |
| Carvedilol | Carvedilol | 37 | 12 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 36 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Nystatin | Nystatin | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Clonidine | Clonidine | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 14 |
| Verapamil Er | Verapamil Hcl | 31 | 11 |
| Levofloxacin | Levofloxacin | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 17 |
| Tramadol Hcl | Tramadol Hcl | 29 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 13 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,523.51 · 74 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, Assure WCD, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, GARDASIL 9, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, REXULTI, Saxenda, The Cologuard Plus Collection Kit, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error